Patents Assigned to LUNDBECK A/S
-
Patent number: 12384837Abstract: Methods for treatment of most bothersome symptom (MBS) associated with migraine are provided. Exemplary methods provide improvement in MBS associated with migraine within 1 month of administration og anti-CGRP antibodies of the invention. Also provided are methods for improvement of patient impression of change (PGIC) associated with migraine. Exemplary methods comprise administration of an anti-CGRP antagonistic antibody to a patient in need thereof.Type: GrantFiled: March 13, 2023Date of Patent: August 12, 2025Assignee: H. Lundbeck A/SInventors: Roger K. Cady, Jeffrey T. L. Smith, Joseph Hirman
-
Patent number: 12384836Abstract: Methods for immediate relief of migraine or headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof.Type: GrantFiled: February 23, 2023Date of Patent: August 12, 2025Assignee: H. Lundbeck A/SInventors: Roger K. Cady, Jeffrey T. L. Smith, Joseph Hirman, Barbara Schaeffler, Lahar Mehta
-
Patent number: 12378219Abstract: Described herein are crystalline forms of the MAGL inhibitor 1,1,1,3,3,3-Hexafluoropropan-2-yl(S)-1-(pyridazin-3-ylcarbamoyl)-6-azaspiro[2.5]octane-6-carboxylate.Type: GrantFiled: May 3, 2023Date of Patent: August 5, 2025Assignee: H. LUNDBECK A/SInventors: Thomas Vetter, John J. M. Wiener, Cheryl A. Grice, Daniel J. Buzard, Justin S. Cisar, Olivia Delene Weber, Amy Allan, Nicholas Raffaele, Jeanne V. Moody, Michael B. Shaghafi
-
Patent number: 12351624Abstract: The present invention relates to stable and low viscosity liquid pharmaceutical compositions comprising antibodies binding to human alpha synuclein and to methods for use of antibodies binding to human alpha synuclein for treating synucleinopathies or prodromal synucleinopathy, incl. suitable doses and/or dosing regimens. These antibodies for use in treatment of synucleinopathies or prodromal synucleinopathy may be formulated in the stable and low viscosity liquid pharmaceutical compositions of the invention.Type: GrantFiled: July 16, 2024Date of Patent: July 8, 2025Assignee: H. Lundbeck A/SInventors: Josefine Nielsen Søderberg, Pekka Kallunki, Louise Buur, Frank Larsen
-
Patent number: 12351627Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for ACTH. Another embodiment of this invention relates to the antibodies binding fragments thereof described herein, comprising the sequences of the VH, VL and/or CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-ACTH antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention further contemplates methods of making said anti-ACTH antibodies and binding fragments thereof.Type: GrantFiled: June 27, 2022Date of Patent: July 8, 2025Assignee: H. LUNDBECK A/SInventors: Andrew Lawrence Feldhaus, Leon Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katie Olson Anderson, Ethan Wayne Ojala, Pei Fan, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Jeffrey T. L. Smith, John Latham
-
Patent number: 12319710Abstract: The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.Type: GrantFiled: May 19, 2020Date of Patent: June 3, 2025Assignee: H. Lundbeck A/SInventors: Morten Jørgensen, Martin Juhl, Klaus Gjervig Jensen
-
Patent number: 12258340Abstract: Provided herein are pyrazole compounds and pharmaceutical compositions comprising the same. The compounds and compositions are useful as modulators of monoacylglycerol lipase (MAGL). Furthermore, the compounds and compositions are useful for the treatment of pain.Type: GrantFiled: March 16, 2023Date of Patent: March 25, 2025Assignee: H. LUNDBECK A/SInventors: Cheryl A. Grice, John J. M. Wiener, Olivia D. Weber, Katharine K. Duncan
-
Patent number: 12258305Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.Type: GrantFiled: July 20, 2022Date of Patent: March 25, 2025Assignee: H. Lundbeck A/SInventors: Mario Rottlander, Anette Graven Sams, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen
-
Patent number: 12226428Abstract: The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.Type: GrantFiled: June 6, 2023Date of Patent: February 18, 2025Assignee: H. Lundbeck A/SInventors: Klaus Gjervig Jensen, Lisbet Kværnø, Morten Jørgensen, Martin Juhl
-
Patent number: 12215145Abstract: Methods for immediate relief of migraine or headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof.Type: GrantFiled: March 19, 2024Date of Patent: February 4, 2025Assignee: H. LUNDBECK A/SInventors: Roger K. Cady, Jeffrey T. L. Smith, Joseph Hirman, Barbara Schaeffler, Lahar Mehta
-
Patent number: 12215144Abstract: Methods for rapid treatment of chronic migraine are provided. Exemplary methods provide relief from migraine within 24 hours of administration. Also provided are methods for acute treatment of migraine. Exemplary methods comprise administration of an anti-CGRP antagonist antibody to a patient in need thereof.Type: GrantFiled: March 19, 2024Date of Patent: February 4, 2025Assignee: H. LUNDBECK A/SInventors: Roger K. Cady, Jeffrey T.L. Smith, Joseph Hirman, Barbara Schaeffler, Lahar Mehta
-
Publication number: 20240425521Abstract: The present invention relates to novel spiro-macrocyclic compounds of general formula (I) which are Orexin 2 receptor agonists.Type: ApplicationFiled: May 31, 2024Publication date: December 26, 2024Applicant: H. Lundbeck A/SInventors: Karsten Juhl, Wanwan Yu, Thomas Leegaard Andersen, Erhad Ascic, Michael Baek, Gitte Kobberøe Mikkelsen, Andreas Michael Arnold, Anders Højgaard Hansen, Petra Lindovská, Henrik Juhani Keränen, Ferran Planas Padrós
-
Patent number: 12162936Abstract: The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.Type: GrantFiled: March 16, 2021Date of Patent: December 10, 2024Assignee: H. LUNDBECK A/SInventors: Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
-
Patent number: 12152029Abstract: Described herein are new crystalline forms of the MAGL inhibitor 1-(1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carbonyl)-1H-pyrazole-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 1, 2022Date of Patent: November 26, 2024Assignee: H. Lundbeck A/SInventors: Thomas Vetter, Martin Juhl, Heidi Lopez De Diego, Cheryl A. Grice, John J. M. Wiener, Daniel J. Buzard, Amy Allan, Susana Del Rio Gancedo, Samuel George Andrew, Antonio Cincotti, Adam Ross Patterson, Richard James Edwards
-
Patent number: 12129289Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.Type: GrantFiled: August 11, 2021Date of Patent: October 29, 2024Assignee: H. Lundbeck A/SInventors: Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
-
Publication number: 20240352055Abstract: The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below and salts thereof. The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease. The invention also relates to new intermediates of said process.Type: ApplicationFiled: November 13, 2023Publication date: October 24, 2024Applicant: H. LUNDBECK A/SInventors: Martin Juhl, Frans Dennis Therkelsen, Tobias Gylling Frihed
-
Patent number: 12122821Abstract: The present disclosure provides methods for the prevention or treatment of metabolic disorders. In exemplary embodiments, methods of administering an anti-CGRP antibody are provided, optionally in combination with a second agent, wherein peripheral and/or hepatic glucose utilization is increased, thereby preventing or treating diseases and disorders associated with insulin resistance. Compositions comprising an anti-CGRP antibody are also provided, optionally in combination with a second agent, which are suitable for administration to increase peripheral and/or hepatic glucose utilization and thereby prevent or treat diseases and disorders associated with insulin resistance.Type: GrantFiled: July 12, 2019Date of Patent: October 22, 2024Assignee: H. LUNDBECK A/SInventors: Brian Baker, Jeffrey T.L. Smith, John Latham
-
Publication number: 20240343741Abstract: The present invention is directed to compounds of formula IIa These compounds are considered useful for the treatment of diseases associated with leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease. Furthermore, the invention relates to pharmaceutical compositions comprising said compounds.Type: ApplicationFiled: February 21, 2024Publication date: October 17, 2024Applicant: H. Lundbeck A/SInventors: Thomas Jensen, Thomas Andersen, Mikkel Jessing, Jacob Nielsen, Henrik Daver, Christopher Richard Jones
-
Patent number: 12116355Abstract: The present invention relates to deuterated 1-piperazino-3-phenyl-indanes and salts thereof with activity at dopamine receptors D1 and D2 as well as the 5HT2 receptors in the central nervous system, to medicaments comprising such compounds as active ingredients, to the use of such compounds in the treatment of diseases in the central nervous system, and to methods of treatment comprising administration of such compounds.Type: GrantFiled: June 7, 2021Date of Patent: October 15, 2024Assignee: H. Lundbeck A/SInventors: Morten Jorgensen, Peter Hongaard Andersen, Klaus Gjervig Jensen
-
Publication number: 20240327336Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.Type: ApplicationFiled: December 6, 2022Publication date: October 3, 2024Applicant: H. Lundbeck A/SInventors: Mario Rottlander, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen, Anette Graven Sams, Krestian Larsen